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ABSTRACT
A substantial proportion of patients with acute graft-versus-host disease (aGVHD) respond to cell
therapy with culture-expanded human bone marrow mesenchymal stromal/stem cells (BM-MSCs).
However, the mechanisms by which these cells can ameliorate aGVHD-associated complications
remain to be clarified. We show here that BM-MSC-derived extracellular vesicles (EVs) recapitu-
lated the therapeutic effects of BM-MSCs against aGVHD. Systemic infusion of human BM-MSC-
derived EVs prolonged the survival of mice with aGVHD and reduced the pathologic damage in mul-
tiple GVHD-targeted organs. In EV-treated GVHD mice, CD41 and CD81 T cells were suppressed.
Importantly, the ratio of CD62L-CD441 to CD62L1 CD44- T cells was decreased, suggesting that
BM-MSC-derived EVs suppressed the functional differentiation of T cells from a naive to an effector
phenotype. BM-MSC-derived EVs also preserved CD41 CD251 Foxp31 regulatory T cell popula-
tions. In a culture of CD3/CD28-stimulated human peripheral blood mononuclear cells with BM-
MSC-derived EVs, CD31 T cell activation was suppressed. However, these cells were not suppressed
in cultures with EVs derived from normal human dermal fibroblasts (NHDFs). NHDF-derived EVs did
not ameliorate the clinical or pathological characteristics of aGVHD in mice, suggesting an immuno-
regulatory function unique to BM-MSC-derived EVs. Microarray analysis of microRNAs in BM-MSC-
derived EVs versus NHDF-derived EVs showed upregulation of miR-125a-3p and downregulation of
cell proliferative processes, as identified by Gene Ontology enrichment analysis. Collectively, our
findings provide the first evidence that amelioration of aGVHD by therapeutic infusion of BM-MSC-
derived EVs is associated with the preservation of circulating naive T cells, possibly due to the
unique microRNA profiles of BM-MSC-derived EVs. STEMCELLS 2018;36:434–445
SIGNIFICANCE STATEMENT
Cell therapy with human bone marrow mesenchymal stromal/stem cells (BM-MSCs) is clinically
effective for patients with intractable acute graft-versus-host disease (aGVHD) after allogeneic
hematopoietic stem cell transplantation. This study revealed that BM-MSC-derived extracellular
vesicles (EVs) recapitulated the therapeutic effects of BM-MSCs against aGVHD by inhibiting
effector T cell induction and preserving peripheral naive T cells. Gene Ontology analysis of
microRNAs differentially expressed in BM-MSC-derived EVs suggested that these microRNAs
may downregulate cell proliferative processes. These findings suggest that BM-MSC-derived EVs
mediate the anti-aGVHD effects of BM-MSCs, thereby raising the possibility of using EVs as a
cell-free therapy for the treatment of aGVHD.
INTRODUCTION
Although molecularly-targeted therapies have
improved the prognosis of patients with hemato-
logical diseases, allogeneic hematopoietic stem
cell transplantation (HSCT) remains the only
curative therapy for refractory disease. Acute
graft-versus-host disease (GVHD) occurs when
immune cells transplanted from a genetically
non-identical donor recognize and are activated
by alloantigens in HSCT recipients, resulting in
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organ damage [1]. Various immunosuppressants have been clini-
cally applied for the prevention of acute GVHD [2]. However, a
substantial proportion of HSCT recipients develop this potentially
life-threatening complication. The efﬁcacy of standard primary
therapy with corticosteroids is about 50%, and the complete
response rate to secondary therapy with a variety of immunosup-
pressants is about 30%, with a median overall survival of less
than 1 year in steroid-refractory patients [3]. Therefore, develop-
ment of novel treatment strategies is extremely important to
improve the overall survival of recipients of HSCT.
Human mesenchymal stromal/stem cells (MSCs) are multi-
potent cells that show a variety of biological characteristics,
including immunomodulatory capacity [4–6]. Clinical studies
have demonstrated the efﬁcacy of systemic infusion of
culture-expanded allogeneic human bone marrow (BM)-MSCs
for the treatment of patients with steroid-refractory acute
GVHD [7]. In some countries, allogeneic bone marrow mesen-
chymal stromal/stem cell (BM-MSC) products are clinically
used as an off-the-shelf product for steroid-resistant acute
GVHD [8]. Previous lines of evidence have suggested that BM-
MSCs inhibit the function of immune cells mainly through the
local secretion of soluble immune modulators and partially
through cell-to-cell contact-dependent mechanisms [9]. How-
ever, because most infused BM-MSCs remain in the lungs,
these observations do not clearly explain the mechanism by
which MSCs can exert “remote” immunomodulatory effects in
GVHD-affected organs.
Recently, extracellular vesicles (EVs) have gained interest
as mediators of cell-to-cell communication based on their
ability to transmit signals to sites of action regardless of phys-
iological barriers [10, 11]. EVs are small membrane particles
released from many types of cells. They contain various types
of molecules, including microRNAs that regulate a diverse
range of biological processes [12]. Several studies have dem-
onstrated that BM-MSC-derived EVs contribute to the immu-
nomodulatory and regenerative effects of MSCs [13]. Most of
these reports show that MSC-derived EVs can recapitulate the
therapeutic and regenerative effects of MSCs on damaged tis-
sues/organs in models of myocardial ischemia [14], acute
tubular injury [15], stroke [16], acute lung injury/ischemia [17,
18], and skin wounds [19]. More recently, a case report
described the successful treatment of a patient with refrac-
tory acute GVHD by intravenous infusions of EVs derived from
BM-MSCs [20]. However, the biologic mechanisms by which
BM-MSC-derived EVs exert these functions remain unknown.
In this study, we examined the effects of human BM-MSC-
derived EVs on the clinical, pathological, and immunologic
characteristics of acute GVHD model mice. A microarray analy-
sis was also conducted to evaluate the biological processes
mediated by microRNAs within human BM-MSC-derived EVs.
MATERIALS AND METHODS
Human BM-MSC Culture
Human MSCs were isolated from BM samples purchased from
AllCells (Alameda, CA) using our previously published method
[21, 22]. BM samples were obtained from three different
healthy adult donors. A single-cell suspension of 1 3 106 BM
mononuclear cells was seeded into a 15 cm culture dish, and
adherent cells were cultured in Advanced Minimal Essential
Medium (Invitrogen/Thermo Fisher Scientiﬁc, Waltham, MA)
supplemented with 5% fetal bovine serum (FBS; Gibco/
Thermo Fisher Scientiﬁc), 100 mM ascorbic acid (Wako Pure
Chemical Industries, Osaka, Japan), 2 mM L-glutamine, 100 U/
ml penicillin, and 100 mg/ml streptomycin (all from Gibco/
Thermo Fisher Scientiﬁc) (complete culture medium, CCM).
Primary cultures were passaged to disperse the colony-
forming cells (passage 1). Cells at passage 3 were used as
BM-MSCs in this study. Prior to use in experiments, surface
marker expression proﬁles of these cells were obtained to
conﬁrm that the cells fulﬁl the minimal deﬁnition criteria for
human MSCs, as proposed by the International Society for
Cellular Therapy [23]. In addition, the multilineage differentia-
tion capacity and hematopoiesis-inducing capacity of these
cells were conﬁrmed as previously described [24, 25]. In some
experiments, normal human dermal ﬁbroblasts (NHDFs) pur-
chased from Lonza (Basel, Switzerland) were cultured using
the FGM-2 Bullket Kit (Lonza), which contains human ﬁbro-
blast growth factor-b, insulin, FBS, and gentamicin/amphoteri-
cin-B.
EV Preparation
Human BM-MSCs (2 3 105 cells) were plated in T-75 culture
ﬂasks in CCM. Seven days later, the CCM was replaced with
10 ml serum-free medium (SFM). The conditioned SFM was
collected after 24 hours and centrifuged at 2,000g for 30
minutes. The supernatant fraction was passed through a 0.2
mm ﬁlter, mixed with Total Exosome Isolation Reagent (Invitro-
gen/Thermo Fisher Scientiﬁc), incubated overnight at 48C, and
centrifuged at 10,000g for 1 hour. The EV-containing pellet
was resuspended in Dulbecco’s phosphate-buffered saline at
100 ml per 1.0 3 106 BM-MSCs. The particle and protein con-
tents of the EVs were measured by tunable resistive pulse
sensing (qNano, Izon Science Ltd, Oxford, U.K.) [26] or by
Bradford protein assay (Thermo Fisher Scientiﬁc), respectively.
The mean protein and particle contents of the EV prepara-
tions were 4.48 mg/ml and 4.23 3 109 particles/ml,
respectively.
Immunoblot Analysis and Transmission Electron
Microscopy
For immunoblot analysis, EVs solutions were lysed with 5X
SDS sample buffer, separated on 4%–12% SDS-PAGE gels (Invi-
trogen/Thermo Fisher Scientiﬁc), and transferred to PVDF
membranes. Primary antibodies against CD63 (clone TS63,
Abcam, London, U.K.) and CD81 (rabbit polyclonal, System
Biosciences, Palo Alto, CA) were used to detect EVs. For trans-
mission electron microscopy, EVs were placed on formvar-
coated copper grids and allowed to absorb onto the grid
overnight. After the excess solution was carefully removed
using ﬁlter paper, the samples were stained with 1% uranyl
acetate for 10 minutes, dried, and observed with a JEOL JEM-
1230S transmission electron microscope operating at 80 KV
(JEOL, Tokyo, Japan).
In Vitro T Cell Expansion Assay
Human peripheral blood mononuclear cells (PBMCs) were
separated using Ficoll-Paque Plus (GE Healthcare Japan, Tokyo,
Japan). PBMCs (1 3 106/well) were activated with anti-CD3
and anti-CD28 antibodies using Human T-Activator CD3/CD28
Dynabeads (Life Technologies/Thermo Fisher Scientiﬁc) in 24-
Fujii, Miura, Fujishiro et al. 435
www.StemCells.com VC 2017 The Authors STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
well plates (25 ml/well) according to the manufacturer’s
instructions (day 0). Five days later (day 5), the number of
cells was counted by Trypan blue dye exclusion and their sur-
face marker expression was assessed by ﬂow cytometry. For
co-culture assays, BM-MSCs (5 3 104/well) were prepared in
24-well plates the day before adding the PBMCs (day -1). To
examine the effects of EVs, 5 ml EVs prepared from condi-
tioned SFM derived from 5 3 104 BM-MSCs was added to
the T cell expansion culture.
Murine Acute GVHD Model
Speciﬁc pathogen-free 7- to 9-week-old C57BL/6 mice (H-2Db),
DBA/2 mice (H-2Dd), and B6D2F1 mice (C57BL/6 3 DBA/2 F1;
H-2Db3d) were obtained from CLEA Japan (Tokyo, Japan). For
induction of GVHD, 1 3 107 spleen cells from parental
C57BL/6 mice (B6) were intravenously injected via the tail
vein into B6D2F1 (BDF1) mice that received 8 Gy total body
irradiation prior to transplantation [27]. GVHD was indicated
by a 10% loss of body weight in the recipient mice [28].
The GVHD mice were randomized into two groups 5 days
after the injection of the spleen cells. The control group
received a tail vein injection of 200 ll saline, and the EV-
treated mice received an injection of 200 ll saline containing
EVs derived from 2 3 106 human BM-MSCs per kg of body
weight; for example, for a mouse weighing 20 g, 4 ml EVs
derived from 4 3 104 human BM-MSCs were prepared and
adjusted to a ﬁnal volume of 200 ml with saline (approxi-
mately 1.6 3 107 particles containing 16 lg protein). The
study was approved by the Committee for Animal Research of
the Kyoto University Graduate School of Medicine (Medkyo
#17284). All animal studies were performed in accordance
with the relevant guidelines and regulations.
Histological and Clinical Assessment of GVHD
For histological assessment, mice were sacriﬁced 6 days after
administration of EVs, and tissue samples from the large
bowel, liver, small bowel, and skin were collected. The sever-
ity of GVHD was scored by evaluating H&E-stained parafﬁn-
embedded sections of these tissues/organs, as previously
described [29]. Seven (for the large and small bowel) or 10
(for the liver) parameters were evaluated and scored as fol-
lows: 0 (normal), 0.5 (rare, focal), 1 (mild, focal), 2 (mild, dif-
fuse), 3 (moderate, diffuse), or 4 (severe, diffuse). Scores
from each parameter were summed for a total score of 0–28
for the large bowel and small bowel, and 0–40 for the liver.
For evaluation of the skin, the severity of damage was evalu-
ated as mild, moderate, or severe by previously described cri-
teria, with some modiﬁcations [30]. Clinical assessment was
performed 10 days after the injection of spleen cells and was
based on ﬁve parameters, including weight loss, posture,
activity, fur texture, and skin integrity, as previously described
[28, 31]. A score of 0 (good) to 2 (poor) for each parameter
was summed, for a total score of 0–10.
Flow Cytometric Analysis
For the analysis of surface marker expression of BM-MSCs,
NHDFs, and murine peripheral blood (PB), a single-cell suspen-
sion of these cells was stained with ﬂuorescent-conjugated anti-
bodies and analyzed on a FACS Canto II (BD Biosciences, Franklin
Lakes, NJ). For the analysis of expanded cells in anti-CD3/CD28-
stimulated human PBMC cultures, the Dynabeads were removed
with a magnet prior to staining. The primary antibodies used in
this study are listed in Supporting Information Table S1. Dead
cells were excluded by staining with propidium iodide. For the
staining of the intracellular protein Foxp3, the Live/Dead Fixable
Blue Dead Cell Stain Kit (Molecular Probes/Thermo Fisher Scien-
tiﬁc) was used to exclude dead cells. Data were analyzed using
FlowJo software (Tree Star, Ashland, OR). The CD3-negative pop-
ulation, as determined by the staining of the isotype control Ab,
included few CD41/CD81 cells.
Microarray Analysis of microRNAs
Total RNA was extracted from human BM-MSC- or NHDF-
derived EVs using the miRNeasy Mini Kit (Qiagen, Hilden, Ger-
many). The integrity of the RNA was evaluated using an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
The extracted total RNA was labeled with Cyanine5 using the
3D-Gene miRNA labeling kit (Toray Industries, Kamakura,
Japan). The microRNA expression proﬁles were examined
using the 3D-Gene miRNA microarray analysis system (Toray
Industries). The mRNA targets of microRNAs were predicted
using TargetScan (http://www.targetscan.org/). Gene Oncology
(GO) enrichment and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analyses were performed using
GeneCodis tools with the predicted targets of each microRNA
as the input (http://genecodis.cnb.csic.es/). The complete
microarray data are available in the NCBI Gene Expression
Omnibus. The microarray accession number is GSE99082.
Array Analysis of Soluble Factors
Soluble factors expressed by human BM-MSC- or NHDF-derived
EVs were analyzed using the Proteome Proﬁler Human Cytokine
Array (R&D Systems, Minneapolis, MN) according to the manu-
facturer’s instructions. EVs were solubilized in Tween 20 (MP Bio-
medicals, Illkirch-Graffenstaden, France) at a ﬁnal concentration
of 1% and sonicated for 60 seconds. Protein prepared from EVs
(300 mg) was mixed with a cocktail of biotinylated detection anti-
bodies and applied to membranes coated with immobilized cap-
ture antibodies. Immunoreactive proteins were detected and
visualized with streptavidin-horseradish peroxidase and chemilu-
minescent detection reagents. Protein expression levels were
measured using Quantity One software (Bio-Rad, Hercules, CA).
Statistical Analysis
Fisher’s exact test was used unless otherwise indicated. Bar
graphs indicate the mean6 SD. Statistical signiﬁcance is
expressed as follows: *, p< .05; **, p< .01. Survival was esti-
mated using the Kaplan–Meier method, and survival estimates
were compared by log-rank testing. Statistical analyses were
performed with the EZR software program [32].
RESULTS
Characteristics of EVs and Their Originated Human
BM-MSCs
An overview of EV preparation from culture supernatants of
human BM-MSCs is shown in Supporting Information Fig. S1A.
EVs from three different lots of BM-MSCs expressed the EV-
associated markers CD63 and CD81 by immunoblot analysis
(Supporting Information Fig. S1B). Transmission electron
microscopy of the prepared EVs identiﬁed particles with a
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saucer-like morphology, as previously described [33, 34] (Sup-
porting Information Fig. S1C). The size of the particles in the
EV preparations ranged from 90 to 400 nm, with most par-
ticles measuring approximately 110 nm (Supporting Informa-
tion Fig. S1D).
When human PBMCs were stimulated with anti-CD3 and
anti-CD28 antibodies in the presence of human BM-MSCs, the
number of expanded cells at 5 days was signiﬁcantly lower
than in cultures of PBMCs stimulated alone (Fig. 1A, 1B). Flow
cytometric analysis showed that the expansion of total T cells
as well as CD41 T cells was substantially suppressed (Fig. 1C–
1E). This suppressive effect was also observed when activated
PBMCs were co-cultured with different lots of BM-MSCs and
when a different lot of activated PBMCs was co-cultured with
Figure 1. Human BM-MSC-derived EVs suppress T cells and preserve naive Treg in vitro. Human peripheral blood mononuclear cells
(PBMCs) were activated with anti-CD3/CD28-coated Human T-Activator Dynabeads. These cells were cultured alone (black bars in A, C,
F; Control in B, D, E, G), co-cultured with BM-MSCs (red bars in A, C, F; BM-MSC in B, D, E, G), or cultured with BM-MSC-derived EVs
(purple bars in A, C, F; EV in B, D, E, G). (A): The number of viable cells was counted by Trypan blue dye exclusion. (B): Representative
phase-contrast images of the cultures. Red arrows indicate PBMCs. Yellow arrows indicate Dynabeads. Bars, 50 lm. Original magniﬁca-
tion, 3200. (C): Flow cytometric analysis showing the percentage of CD31 T cells and the percentages of CD41 and CD81 T cells out
of total CD31 T cells. (D, E): Representative contour plots are shown. The numbers represent the percentage of CD31 T cells or the
percentages of CD41 and CD81 T cells out of total CD31 T cells. The CD3-negative cell population, as determined by staining with iso-
type control antibodies, included few T cells (CD41 or CD81). (F, G): Flow cytometric analysis of three fractions of Foxp3-expressing
cells, Fraction 1 (Fr1; CD45RA1Foxp3low naive Treg), Fraction 2 (Fr2; CD45RA-Foxp3high activated Treg), and Fraction 3 (Fr3; CD45RA-Fox-
p3low non-Treg). (F) The frequency of each Foxp3-expressing cell fraction out of total CD41 T cells and the ratio of CD81 T cells to each
Foxp3-expressing cell fraction are shown. (G) Representative contour plots are shown. The numbers indicate the percentage of each
fraction out of all CD41 T cells. Data in (A, C, F) represent the mean6 SD. **, p< .01; *, p< .05. Abbreviations: BM-MSC, bone marrow
mesenchymal stromal/stem cell; EVs, extracellular vesicles; SSC, side scatter.
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the BM-MSCs (Supporting Information Fig. S2A, 2B). The
PBMCs and MSCs were mismatched by at least six out of
eight human leukocyte antigen (HLA) alleles (Supporting Infor-
mation Table S2). Therefore, BM-MSC lots used in this study
could suppress the expansion of T cells in an HLA-
independent manner, as previously demonstrated [6, 35].
Human BM-MSC-Derived EVs Suppress the Expansion
of Effector T Cells but Preserve Naive Regulatory T
Cells In Vitro
The effect of EVs on the expansion of functional T cell subsets
was evaluated in cultures of anti-CD3/CD28-stimulated
PBMCs. In the presence of human BM-MSC-derived EVs, the
expansion of anti-CD3/CD28-stimulated human PBMCs was
suppressed (Fig. 1A, 1B). The expansion of total T cells, includ-
ing CD41 T cells, was suppressed in a manner similar to co-
cultures with BM-MSCs (Fig. 1C–1E). The expansion of CD81
T cells was also suppressed in the presence of EVs, but not in
co-cultures with BM-MSCs (Fig. 1C–1E). When the supernatant
fraction generated in the process of EV preparation was used
instead of EVs in the expansion cultures, these suppressive
effects were not observed (Supporting Information Fig. S1A,
1E, 1F). The EV-mediated suppressive effects were observed
when anti-CD3/CD28-stimulated PBMCs were cultured in the
presence of different lots of BM-MSC-derived EVs (Supporting
Information Fig. S2A), and when different lots of PBMCs were
cultured in the presence of BM-MSC-derived EVs (Supporting
Information Fig. S2B).
Previous studies suggested that regulatory T cells (Treg) may
be associated with the immunomodulatory functions of BM-
MSCs [6]. We therefore examined whether BM-MSC-derived EVs
inﬂuence Treg. In the anti-CD3/CD28-stimulated PBMC expansion
cultures, the frequency of CD45RA1 Foxp3low naive Treg (Frac-
tion 1) was higher, and the frequency of CD45RA-Foxp3high effec-
tor Treg (Fraction 2) was lower, in the presence of EVs (Fig. 1F,
1G). In addition, the ratio of total CD81 T cells to naive Treg was
lower in the presence of EVs (Fig. 1F, 1G). Finally, the frequency
of CD45RA-Foxp3low non-Treg (Fraction 3) was lower in cultures
with EVs compared to cultures of PBMCs alone, suggesting the
suppression of non-Treg within the Foxp3-expressing T cell popu-
lation by BM-MSC-derived EVs. Collectively, these data demon-
strate that BM-MSC-derived EVs preserve naive Treg.
With regard to other hematopoietic cell populations, the
frequency of CD191 cells, CD3-CD561 cells, CD3-CD161 cells,
CD11b1 cells, and CD3-CD4dim cells remained high in the
expansion cultures of PBMCs containing EVs (Supporting Infor-
mation Fig. S3). These results suggested that EVs speciﬁcally
suppress the expansion of T cells, but not B cells, NK cells, or
mature myeloid cell populations. In particular, B cells and
mature myeloid cell populations seemed to be preserved in the
expansion cultures with EVs (Supporting Information Fig. S3).
Human BM-MSC-Derived EVs Ameliorate the Clinical
and Pathological Characteristics of Acute GVHD in
Mice
To investigate the effects of BM-MSC-derived EVs on acute
GVHD in vivo, a major histocompatibility complex (MHC)-hap-
loidentical murine model was used in which 1 3 107 spleen
cells from C57BL/6 mice (B6, H-2Db) were injected into
B6D2F1 (BDF1, H-2Db3d) mice. These mice were randomly
divided into two groups 5 days after the injection of spleen
cells. One group of GVHD mice was treated with human BM-
MSC-derived EVs, and the other group of mice received saline
injections (Fig. 2A). GVHD mice that received systemic infu-
sion of EVs showed prolonged survival, with a median survival
of 16 days compared with 10 days in the control GVHD mice
(Fig. 2B). The clinical scores of EV-treated mice were lower
than those of the control mice (average of 2.8 vs. 3.5, Fig.
2C), indicating that EVs ameliorated the systemic symptoms of
acute GVHD such as body weight loss. EV treatment also sig-
niﬁcantly mitigated GVHD-associated pathology in the large
bowel, particularly the inﬁltration of the lamina propria by
inﬂammatory cells and the vacuolization and attenuation of
surface colonocytes (Fig. 2D–2F). The histological scores of the
livers of the EV-treated GVHD mice were lower than those of
the control mice, but this did not reach statistical signiﬁcance,
and the histological scores of the small bowels of the EV-
treated mice were comparable to those of the control mice
(Fig. 2D, Supporting Information Fig. S4B; Supporting Informa-
tion Table S3). With regard to the skin, the percentage of
mice with severe damage was lower in the EV-treated group
than in the control group (60.0% vs. 88.8%) (Fig. 2G, Support-
ing Information Fig. S4B; Supporting Information Table S4).
Collectively, systemic administration of human BM-MSC-
derived EVs signiﬁcantly prolonged the survival of mice with
acute GVHD, which was accompanied by an amelioration of
clinical GVHD symptoms and pathological damage in multiple
GVHD-targeted organs, particularly the large bowel.
Human BM-MSC-Derived EVs Suppress the Functional
Differentiation of T Cells in Mice with GVHD
PB T cell subsets were analyzed in GVHD mice that received sys-
temic administration of EVs. Flow cytometric analysis indicated
that the expansion of CD81 T cells was suppressed by treat-
ment with human BM-MSC-derived EVs (Fig. 3A, 3B). In the con-
trol GVHD mice, most of the CD81 and CD41 T cells were
CD62L-CD441 effector T cells (Fig. 3C, Supporting Information
Fig. S5B, 5D). In GVHD mice treated with EVs, the frequency and
number of effector T cells among CD41 and CD81 T cells were
decreased, and conversely, the frequency and number of
CD62L1CD44- naive T cells were increased (Fig. 3C, Supporting
Information Fig. S5A–5D). These results suggest that systemic
administration of human BM-MSC-derived EVs suppressed the
functional differentiation of T cells from a naive phenotype to
an effector phenotype. The frequency of CD41 CD251 Foxp31
Treg was also decreased in the GVHD control mice compared
to mice without GVHD, whereas the EV-treated GVHD mice
contained a substantial CD41 CD251 Foxp31 population (Fig.
3D), suggesting that human BM-MSC-derived EVs preserve Treg.
The populations of non-T cells, including CD191Gr-1- cells
(B cells), Gr-1-CD11b1 cells (monocytes), and Gr-11 CD11b1
cells (neutrophils), were depleted in the control GVHD mice
compared to mice without GVHD, but EV treatment ameliorated
the depletion of these cell populations (Supporting Information
Fig. S6).
NHDF-Derived EVs Do Not Suppress T Cell Expansion
In Vitro or Ameliorate Acute GVHD in Mice
We explored whether the anti-GVHD effects of BM-MSC-
derived EVs could be induced by EVs derived from other stromal
cells. To address this, we used NHDFs because they are adherent
stromal cells with a similar morphology to human BM-MSCs.
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Figure 2. Human bone marrow mesenchymal stromal/stem cell (BM-MSC)-derived EVs ameliorate the clinical and pathological charac-
teristics of GVHD in mice. (A): Schema of the EV treatment study. IR, irradiation; IV, intravenous infusion. (B): Survival curves of the
GVHD mice that received human BM-MSC-derived EVs (EV, red line) or saline (Control, black line). The survival of the mice was observed
until day 100 and plotted as a Kaplan–Meier curve (n5 30 for EV-treated GVHD mice; n5 32 for control GVHD mice). **, p< .01. (C):
Clinical scores of the GVHD mice 10 days after the injection of spleen cells. Scores from ﬁve GVHD-associated parameters were
summed, from 0 to 10 (n5 28 for EV-treated GVHD mice; n5 18 for control GVHD mice). (D): Histological scores of the GVHD mice.
Scores from multiple GVHD-associated parameters were summed, from 0 to 28 for the large bowel and small bowel and from 0 to 40
for the liver (n5 5 for EV-treated GVHD mice; n5 8 for control GVHD mice). (E): Histological scores of seven parameters in the large
bowel. (F): Representative microscopic images of H&E-stained sections of large bowel specimens from the mice. Bars, 100 lm. Original
magniﬁcation, 3100. White and black bars in (C–E) indicate the scores of GVHD mice that received BM-MSC-derived EVs (EV) or saline
(Control). (G): Histological evaluation of skin specimens from the GVHD mice. The percentage of mice whose severity of damage was
evaluated as moderate (black) or severe (white) is shown (n5 5 for EV-treated GVHD mice; n5 9 for control GVHD mice). In (D, E, G),
the scores were assessed 6 days after the administration of EVs. Data in (C–E) indicate the mean6 SD. **, p< .01; *, p< .05.
Abbreviations: EVs, extracellular vesicles; GVHD, graft-versus-host disease.
Flow cytometric analysis showed that NHDFs were negative for
hematopoietic and endothelial markers, including CD45, CD34,
CD11b, CD19, CD31, and HLA-DR, and were positive for mesen-
chymal stem cell-associated markers, including CD105, CD73,
CD90, CD44, and CD166, which was a similar expression pattern
as BM-MSCs (Supporting Information Fig. S7A, 7B). On the other
hand, NHDFs were distinct from BM-MSCs in the expression of
CD10, CD106, and CD146 (Supporting Information Fig. S8A). In
addition, NHDFs did not show apparent multi-differentiation
capability to osteogenic (Supporting Information Fig. S8B, 8C),
chondrogenic (Supporting Information Fig. S8D), or adipogenic
(Supporting Information Fig. S8E, 8F) cells in vitro. Moreover,
unlike BM-MSCs, NHDFs did not form bone or induce hemato-
poietic marrow when subcutaneously transplanted into immu-
nocompromised mice (Supporting Information Fig. S8G). Thus,
NHDFs were fundamentally different from BM-MSCs.
When anti-CD3/CD28-stimulated human PBMCs were cul-
tured with NHDF-derived EVs, the expansion of total T cells,
including CD41 and CD81 T cells, was comparable to that in
cultures of PBMCs alone and in cultures with the supernatant
fraction generated in the process of EV preparation from con-
ditioned SFM of NHDFs (Supporting Information Fig. S9A, 9B).
Therefore, NHDF-derived EVs did not have the suppressive
effects on T cells seen with BM-MSC-derived EVs.
In accordance with these observations, when MHC-
haploidentical GVHD mice received NHDF-derived EVs, the
survival of the mice was not prolonged and was actually
shortened compared to the control mice (Supporting Informa-
tion Fig. S10A). The clinical scores of the GVHD mice treated
with NHDF-derived EVs were comparable to those of the con-
trol GVHD mice (Supporting Information Fig. S10B). In addi-
tion, the histological scores for the large bowel, liver, and
small bowel of GVHD mice treated with NHDF-derived EVs
were comparable to those of the control GVHD mice (Sup-
porting Information Fig. S10C). With regard to the skin, in the
mice treated with NHDF-derived EVs, the percentage of mice
with severely damaged skin was lower, and conversely, the
percentage of mice with mildly or moderately damaged skin
was higher compared to the control mice (Supporting Infor-
mation Fig. S10D). Flow cytometric analysis of PB T cell sub-
sets in GVHD mice indicated that the expansion of CD81 T
cells was not suppressed by treatment with NHDF-derived EVs
(Supporting Information Fig. S10E). In addition, the frequency
of effector T cells, naive T cells, and Treg in GVHD mice
treated with NHDF-EVs was comparable to that in the control
GVHD mice (Supporting Information Fig. S10E, 10F). Collec-
tively, these data indicate that systemic administration of
NHDF-derived EVs had no signiﬁcant effect on the functional
differentiation of T cells from a naive phenotype to an effec-
tor phenotype or on the preservation of Treg. These data sug-
gest that the immunologic and anti-GVHD effects of human
BM-MSC-derived EVs are unique, at least in comparison to
NHDF-derived EVs.
Proliferation-Related Gene Signatures Are
Downregulated by microRNAs in Human BM-MSC-
Derived EVs
The expression of multiple soluble factors such as cytokines,
chemokines, and growth factors in NHDF-derived and BM-
MSC-derived EVs was compared (Supporting Information Fig.
S11). Differences in the expression of several molecules,
including macrophage migration inhibiting factor, interleukin
(IL)-13, plasminogen activator inhibitor-1, and CXCL12, were
observed.
Figure 3. Human bone marrow mesenchymal stromal/stem cell
(BM-MSC)-derived EVs preserve peripheral naive T cells and Treg
in mice with GVHD. Flow cytometric analysis of T cell subsets in
PB from the GVHD mice 6 days after the administration of EVs.
(A): The frequency of CD81 and CD41 T cells. (B): Representa-
tive contour plots are shown. (C): The frequency of naive (Tn;
CD62L1CD44-), effector (Teff; CD62L-CD441), and central mem-
ory and effector memory (Tcm and Tem; CD62L1CD441) T cells
out of total CD81 and CD41 T cells. (D): Flow cytometric analysis
of Treg. The numbers indicate the percentage of Treg out of total
CD41 T cells in the PB. No GVHD, BDF1 mice that did not receive
spleen cells from B6 mice; Control GVHD, BDF1 mice that
received spleen cells from B6 mice (H-2Db) but did not receive
human BM-MSC-derived EVs; EV-treated GVHD, BDF1 mice that
received spleen cells from B6 mice and then received human
BM-MSC-derived EVs. Data in (A, C) indicate the mean6 SD. **,
p< .01; *, p< .05. Abbreviations: EVs, extracellular vesicles;
GVHD, graft-versus-host disease.
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Finally, microarray analysis of microRNAs in BM-MSC-
derived EVs was performed (Supporting Information Fig. S12).
This analysis identiﬁed 336 and 337 microRNAs that were
upregulated or downregulated, respectively, in human BM-
MSC-derived EVs compared to NHDF-derived EVs (Fig. 4A,
Supporting Information S-File 1). Among them, miR-125a-3p
was identiﬁed as the most highly upregulated microRNA in
BM-MSC-derived EVs (Fig. 4B). TargetScan analysis predicted
11726 mRNAs as targets of the top 10 upregulated microRNAs
(Supporting Information S-File 2). Among them, 3477 mRNAs
were commonly targeted by three or more microRNAs and
were selected for further analysis. GO enrichment analysis
showed that these commonly targeted genes were highly
involved in the regulation of proliferation-related processes
(Table 1). A similar analysis was performed on 12553 mRNAs
that were predicted as targets of the top 10 downregulated
microRNAs (Fig. 4B, Supporting Information S-File 3). Among
them, 4356 mRNAs were commonly targeted by three or
more microRNAs, and these mRNAs were found to be highly
involved in inhibition of proliferation by GO enrichment
Figure 4. Microarray analysis of microRNAs in BM-MSC-derived EVs versus NHDF-derived EVs. (A): Scatter plot of microRNAs expressed
in BM-MSC-derived EVs compared with NHDF-derived EVs. Blue lines indicate the 2.0-fold threshold. Circles represent the top 10 upre-
gulated microRNAs in BM-MSC-derived EVs. Squares represent the top 10 downregulated microRNAs in BM-MSC-derived EVs. (B): List of
the top 10 microRNAs that were up- or downregulated in BM-MSC-derived EVs. The color of the numbers corresponds to the color of
the circles or squares in the scatter plot in (A). (C): Kyoto Encyclopedia of Genes and Genomes pathway analysis of mRNAs that were
commonly targeted by three or more microRNAs among the top 10 up- or downregulated microRNAs. Abbreviations: BM-MSC, bone
marrow mesenchymal stromal/stem cell; EVs, extracellular vesicles; NHDF, normal human dermal ﬁbroblasts.
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analysis (Table 1). Collectively, these analyses suggest that
microRNAs within BM-MSC-derived EVs downregulate cell pro-
liferation. Furthermore, KEGG pathway analysis identiﬁed
gene groups involved in cell cycle regulation, T cell receptor
signaling, and GVHD (Fig. 4C). These pathways were consid-
ered to be downregulated because they include genes tar-
geted by commonly upregulated microRNAs.
DISCUSSION
A series of clinical studies have examined the efﬁcacy of sys-
temic infusion of culture-expanded BM-MSCs for acute GVHD
patients and shown overall response rates ranging from about
30%–80% [36, 37]. Attempts to improve the outcome of BM-
MSC therapy have been based on the concept that this form
of therapy is dependent on the number of infused cells that
can successfully trafﬁc to sites of damaged or diseased tissue
[38]. However, systemic administration of an increased num-
ber of cells did not augment the therapeutic effects of BM-
MSCs in GVHD [39]. In addition, another approach, in which
BM-MSCs were directly delivered into the gut via the mesen-
teric artery, was not more effective than systemic injection
[40]. These clinical results underscore the current molecular
understanding that the therapeutic effects of BM-MSCs are,
at least in acute GVHD, attributed mainly to secreted
immune-modulatory factors [9, 41]. In the present study, we
found, for the ﬁrst time, that human BM-MSC-derived EVs
ameliorated GVHD symptoms and pathology in GVHD-
targeted organs, and prolonged the survival of GVHD mice in
association with preservation of circulating naive T cell
populations.
BM-MSCs suppress the expansion of human naive T cells
as well as activated CD41 and CD81 T cells regardless of
MHC compatibility [41, 42]. It has also been reported that
BM-MSCs induce human Treg, which inhibit allogeneic lym-
phocyte proliferation [43, 44]. In line with these reports, we
found that BM-MSC-derived EVs suppressed the proliferation
of CD41 and CD81 T cells in anti-CD3/CD28-stimulated
expansion cultures of human PBMCs and in PB obtained from
the GVHD mice. In addition, BM-MSC-derived EVs suppressed
the functional differentiation of T cells from a naive to an
effector phenotype in the GVHD mice. Moreover, naive Treg
were preserved in the presence of BM-MSC-derived EVs in
cultures of anti-CD3/CD28-stimulated human PBMCs and in
PB of the GVHD mice. Collectively, it is conceivable that the
anti-GVHD effect of BM-MSCs is, at least partially, associated
with an EV-mediated immunomodulatory effect on T cells.
However, a number of studies suggest that MSC-derived
EVs mimic the therapeutic effects of their MSCs of their origin
to a large extent, even though the underlying mechanisms
may not necessarily be similar [13]. In our in vitro study, BM-
MSCs suppressed the expansion of CD31 T cells to a lesser
extent than EVs derived from the same number of the BM-
MSCs from which they originated. BM-MSC-derived EVs may,
therefore, have a stronger effect on T cell suppression than
BM-MSCs. This is supported by the observation that the sup-
pressive effect of EVs on T cell expansion was dose-dependent
(data not shown). With respect to the Foxp3-expressing T cell
population, the suppression of CD45RA-Foxp3low cells (non-
Treg) by BM-MSC-derived EVs might reﬂect the suppression of
activated CD41 T cells. Given that CD45RA1 Foxp3low naive
Treg become CD45RA-Foxp3high Treg upon anti-CD3/CD28
stimulation, it is possible that BM-MSC-derived EVs had the
enhanced suppressive effect on the ability of Treg to shift
from a naive to an activated status or that BM-MSC-derived
EVs induced more naive Treg within the CD41 T cell popula-
tion compared to BM-MSCs. Previous in vitro studies on the
modulation of functional T cell populations by BM-MSCs have
been contradictory [45–47]. As for in vivo studies, a recent
report suggested that EVs contribute to the suppression of
Th1 cells in a human-to-mouse xenogeneic chronic GVHD
model [48]. Further studies are needed to determine the con-
tribution of EVs to the BM-MSC-mediated T cell modulation.
Various types of cells release EVs. To address the unique
effects of human BM-MSC-derived EVs, we used NHDF-
derived EVs as a control because human BM-MSCs and ﬁbro-
blasts share many properties, including a plastic-adherent
spindle-like morphology and a similar surface marker
expression proﬁle [49]. Nevertheless, NHDFs are functionally
different from BM-MSCs. In our analysis, NHDFs lacked
multi-differentiation capacity and hematopoiesis induction. In
addition, NHDF-derived EVs did not suppress T cell expansion
Table 1. List of enriched GO terms. GO analysis of commonly targeted genes by up- or downregulated microRNAs in bone marrow mes-
enchymal stromal/stem cell-derived extracellular vesicles
GO accession GO term (number of genes included)
Corrected
p-value microRNA
0008284 Positive regulation of cell proliferation (93) 4.20 E –16 Upregulated
0008285 Negative regulation of cell proliferation (86) 2.28 E –09 Downregulated
0007049 Cell cycle (79) 2.49 E –06 Upregulated
0008283 Cell proliferation (64) 5.82 E –07 Upregulated
0051301 Cell division (47) 2.11 E –03 Upregulated
0000278 Mitotic cell cycle (43) 1.39 E –02 Upregulated
0000082 G1/S transition of mitotic cell cycle (29) 1.49 E –03 Upregulated
0007067 Mitosis (29) 1.42 E –02 Upregulated
0007050 Cell cycle arrest (28) 6.70 E –03 Downregulated
0030307 Positive regulation of cell growth (13) 6.91 E –03 Upregulated
0051781 Positive regulation of cell division (13) 2.43 E –03 Upregulated
0045786 Negative regulation of cell cycle (11) 1.48 E –02 Downregulated
0045787 Positive regulation of cell cycle (8) 8.83 E –03 Upregulated
0045930 Negative regulation of mitotic cell cycle (5) 4.67 E –02 Downregulated
0071158 Positive regulation of cell cycle arrest (5) 3.04 E –02 Downregulated
Abbreviation: GO, Gene Oncology.
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in cultures with anti-CD3/CD28-stimulated PBMCs. Most
importantly, NHDF-derived EVs did not exhibit the anti-GVHD
effects of BM-MSC-derived EVs, including amelioration of clini-
cal symptoms, resolution of the pathology in the gut and liver,
or prolongation of survival. These results suggest that BM-
MSC-derived EVs have a unique therapeutic effect in acute
GVHD. Interestingly, systemic infusion of human BM-MSC-
derived EVs was effective in resolving the pathology in the
large bowel and skin of the GVHD mice. This is consistent
with the clinical characteristics of BM-MSC therapy for acute
GVHD [7, 8, 50, 51]. The mechanisms that underlie the differ-
ences in the efﬁcacy of BM-MSC-derived EVs among organs/
tissues have not been well-studied.
There are limitations to this study. First, the effects of BM-
MSC-derived EVs on GVHD-targeted organs were modest. Only
the suppression of GVHD pathology in the large intestine was sig-
niﬁcantly associated with clinical improvement in GVHD mice
treated with BM-MSC-derived EVs. Although multiple organs can
be affected in GVHD, pathologic damage to the large intestine
can be lethal; therefore, favorable effects of BM-MSC-derived EVs
on the large intestine might predominantly contribute to the
improved clinical outcomes. Second, the survival of GVHD mice
treated with NHDF-derived EVs was less than that of the control
GVHD mice, despite the lack of effects on PB T cells. This suggests
the possibility that the distribution of T cell subsets in the PB
does not reﬂect the distribution in GVHD-targeted organs.
Comprehensive characterization of EVs would provide the
information necessary to explore their therapeutic potential [52].
A previous study by Phinney et al. reported the microRNA expres-
sion proﬁles of MSC-derived exosomes [53]. Because they com-
pared microRNA expression levels between exosomes and their
parental MSCs, the most highly up- or downregulated microRNAs
were different from the most highly regulated microRNAs in our
analysis. However, it is of interest that such microRNAs in that
study were also upregulated in EVs in our analysis. MicroRNAs that
are expressed differentially in EVs compared with the parental
MSCs might contribute to MSC-associated functions.
Microarray analysis of microRNAs in BM-MSC-derived EVs
versus NHDF-derived EVs revealed the differential expression
of multiple microRNAs, suggesting the involvement of multiple
biological processes. Previous studies have demonstrated that
BM-MSCs inhibit the proliferation of activated T cells via cell
cycle arrest [54, 55] and modulate the expression of various
cytokines, including proinﬂammatory (e.g., IL-2, IFN-g, TNF-a)
and anti-inﬂammatory cytokines (e.g., IL-4, IL-10), which play
important roles in the pathogenesis of acute GVHD [6, 9,
56–59]. The GO enrichment analysis identiﬁed the down-
regulation of multiple cell proliferation-related processes but
not altered production of these cytokines. Furthermore, KEGG
analysis suggested the downregulation of pathways associated
with GVHD and T cell receptor signaling. These comprehensive
analyses support our in vitro and in vivo results, where T cell
expansion was suppressed by BM-MSC-derived EVs and acute
GVHD was suppressed clinically and pathologically in GVHD
mice.
Of the microRNAs that were differentially expressed in
human BM-MSC-derived EVs and NHDF-derived EVs, miR-125a-
3p was the most highly altered microRNA. Notably, miR-125a-3p
suppressed cell proliferation in several cell lines, consistent with
our in vitro observations [60–62]. It has also been shown that
miR-125a is downregulated in PBMCs from patients with systemic
lupus erythematosus [63]. The downregulation of miR-125a con-
tributed to the elevated expression of the inﬂammatory chemo-
kine regulated upon activation, normal T cell expressed and
secreted by targeting Kruppel-like factor 13 in activated T cells
[64]. Therefore, the upregulation of miR-125a-3p in BM-MSC-
derived EVs might contribute to the suppression of T cells. Collino
et al. performed microarray analysis of microRNAs contained in
EVs released from both BM-MSCs and liver-resident stem cells
[65]. Although miR-125a was not speciﬁcally discussed by the
authors, it was one of the most abundantly expressed microRNAs
in microvesicles and their cells of origin. Their analysis indicated
that abundantly expressed microRNAs in BM-MSCs contributed
to multiple cell processes, including regulation of the immune
system, differentiation-related functions, and processes related
to the regulation of cell cycle progression, proliferation, and cell
death. One microRNA can regulate many target genes, while con-
versely one gene can be targeted by many microRNAs; thus mul-
tiple relationships between microRNAs and target genes
elaborately determine the fate of T cells. It will be important to
use a conditional microRNA-125a-3p knockout mouse model to
more conclusively demonstrate the association between upregu-
lated microRNA-125a-3p and the anti-GVHD effect.
Array analysis of multiple soluble factors identiﬁed several
molecules that were more highly expressed in BM-MSC-
derived EVs than in NHDF-derived EVs. Among them, CXCL12
could potentially be associated with the amelioration of
GVHD, as was reported in a previous study [66]. EVs contain a
variety of bioactive molecules, and further analysis of
immune-modulatory factors is warranted to fully understand
the anti-GVHD mechanism of BM-MSC-derived EVs.
Use of BM-MSC-derived EVs may have potential advan-
tages over their cell of origin in some aspects. From a safety
standpoint, concerns about the transformation of BM-MSCs to
malignant cells in patients do not need to be considered with
the use of EVs. From a therapeutic standpoint, BM-MSCs may
become trapped in capillaries, particularly in the lungs, and
become unable to reach damaged or diseased tissues/organs,
which is necessary for them to exert their therapeutic effects.
This is also not a concern with EVs. On the other hand, BM-
MSCs are activated by proinﬂammatory cytokines present in
the microenvironment of damaged or diseased tissues/organs
[67]. This implies that the immunomodulatory effects of BM-
MSCs might not be exerted in the absence of abnormal envi-
ronmental conditions. Our study suggests that BM-MSC-
derived EVs have therapeutic effects in acute GVHD. However,
the EVs showed strong suppression of T cell activation in vitro,
and extreme immunosuppression by BM-MSC-derived EVs
may increase susceptibility to infection in a clinical setting. In
addition, because EVs are small, spherical membrane frag-
ments and may include exosomes, microvesicles, and apopto-
tic bodies [33], there is a possibility that the BM-MSC-derived
EV-concentrated fractions in this study contain the above par-
ticles [68]. Therefore, additional research incorporating more
homogenous EV preparations is warranted.
CONCLUSION
Human BM-MSC-derived EVs exerted immunomodulatory effects
on T cells in vitro and anti-GVHD effects in mice. Amelioration of
acute GVHD by BM-MSC-derived EVs was associated with the
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preservation of circulating naive T cells. Microarray analysis iden-
tiﬁed microRNAs associated with the immunomodulatory effects
of BM-MSC-derived EVs. Further studies are needed to increase
the potency of BM-MSC-derived EVs and to better understand
the mechanisms of action of this novel potential therapeutic for
acute GVHD.
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